HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 42, 35598-35605, October 21, 2005

This Article Full Text Full Text (PDF) All Versions of this Article: 280/42/35598    most recent M504544200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Urquiza, M. Articles by Patarroyo, M. E. Search for Related Content PubMed PubMed Citation Articles by Urquiza, M. Articles by Patarroyo, M. E. Social Bookmarking                      What's this?

Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells^*

Mauricio Urquiza1, Ramses Lopez, Helena Patiño, Jaiver E. Rosas, and Manuel E. Patarroyo

From the Fundación Instituto de Inmunología de Colombia and Department of Chemistry and Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 030405, Colombia

Epstein-Barr virus (EBV) invasion of B-lymphocytes involves EBV gp350/220 binding to B-lymphocyte CR2. The anti-gp350 monoclonal antibody (mAb)-72A1 Fab inhibits this binding and therefore blocks EBV invasion of target cells. However, gp350/220 regions interacting with mAb 72A1 and involved in EBV invasion of target cells have not yet been identified. This work reports three gp350/220 regions, defined by peptide 11382, 11389, and 11416 sequences, that are involved in EBV binding to B-lymphocytes. Peptides 11382, 11389, and 11416 bound to CR2(+) but not to CR2(-) cells, inhibited EBV invasion of cord blood lymphocytes (CBLs), were recognized by mAb 72A1, and inhibited mAb 72A1 binding to EBV. Peptides 11382 and 11416 binding to peripheral blood lymphocytes (PBLs) induced interleukin-6 protein synthesis in these cells, this phenomenon being inhibited by mAb 72A1. The same behavior has been reported for gp350/220 binding to PBLs. Anti-peptide 11382, 11389, and 11416 antibodies inhibited EBV binding and EBV invasion of PBLs and CBLs. Peptide 11382, 11389, and 11416 sequences presented homology with the C3dg regions coming into contact with CR2 (C3dg and gp350 bound to similar CR2 regions). These peptides could be used in designing strategies against EBV infection.

Received for publication, April 26, 2005 , and in revised form, July 20, 2005.

^* This research was supported by the Office of the President of the Republic of Colombia. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Virology Group, Fundación Instituto de Inmunología de Colombia, Cra 50, 26-00, Bogotá, Colombia. Tel.: 57-1-4815269 or 57-1-4815219; Fax: 57-1-3244672 (ext. 108); E-mail: mauricio_urquiza{at}fidic.org.co.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A.-D. Gu, Y.-B. Xie, H.-Y. Mo, W.-H. Jia, M.-Y. Li, M. Li, L.-Z. Chen, Q.-S. Feng, Q. Liu, C.-N. Qian, et al. Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology J. Gen. Virol., May 1, 2008; 89(5): 1152 - 1158. [Abstract] [Full Text] [PDF]

				K. A. Young, X. S. Chen, V. M. Holers, and J. P. Hannan Isolating the Epstein-Barr Virus gp350/220 Binding Site on Complement Receptor Type 2 (CR2/CD21) J. Biol. Chem., December 14, 2007; 282(50): 36614 - 36625. [Abstract] [Full Text] [PDF]

				F. C. Hsiao, M. Lin, A. Tai, G. Chen, and B. T. Huber Cutting Edge: Epstein-Barr Virus Transactivates the HERV-K18 Superantigen by Docking to the Human Complement Receptor 2 (CD21) on Primary B Cells J. Immunol., August 15, 2006; 177(4): 2056 - 2060. [Abstract] [Full Text] [PDF]